Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

  • STATUS
    Recruiting
  • participants needed
    21
  • sponsor
    Shanghai Cell Therapy Group Co.,Ltd
Send
Updated on 19 February 2024
See if I qualify

Summary

This is an open-label, multicenter, dose-escalation phase 1 study to determine the Safety and Efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.

Description

This is an open-label, multicenter, phase 1 study to determine the safety, PK, and antitumor activity of BZ019 in adult subjects with R/R large CD19+B cell lymphoma. The safety and efficacy of a single dose of different target doses of BZ019 will be evaluated in the dose-escalation phase and dose-expansion phase.

Primary objectives:

  • To evaluate the safety and tolerance of single infusion of BZ019 in adult patients with relapsed or refractory large B-cell lymphoma, and to determine the maximum tolerable dose (MTD) and phase II recommended dose.

Secondary objectives

  • To evaluate the pharmacokinetics and survival of BZ019 in the peripheral blood of adult patients with relapsed or refractory large B-cell lymphoma;
  • To evaluate the Pharmacodynamic characteristics of BZ019 in adult patients with relapsed or refractory large B-cell lymphoma;
  • Objective response rate (ORR), Overall survival, progression free survival, event free survival, and tumor progression time were used to evaluate the antitumor efficacy of BZ019 in the treatment of relapsed or refractory large B-cell lymphoma.

Details
Condition Large B-cell Lymphoma
Age 18years - 100years
Treatment BZ019
Clinical Study IdentifierNCT04250324
SponsorShanghai Cell Therapy Group Co.,Ltd
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Written informed consent must be obtained prior to any screening procedures
Age 18 years subjects with Relapsed or refractory large B-cell lymphoma, only DLBCL non-specific type, primary mediastinal large B-cell lymphoma, follicular lymphoma transformed large B-cell lymphoma, advanced B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, advanced B-cell lymphoma non-specific type. The definition of refractory is as follows
no response to the last treatment, including:The best response to the latest treatment is disease progression (PD), or the best response to the latest treatment plan is disease stability (SD) and the maintenance time is not more than 6 months after the last administration
or not suitable for autologous hematopoietic stem cell transplantation (ASCT), or ASCT refractory, including: disease progression after ASCT or recurrence within 12 months (recurrence must be confirmed by biopsy), or if receiving remedial treatment after ASCT, the subject must have no reaction or recurrence after the last treatment
Subjects must be accepted adequate treatment before and have received at least 2 lines of treatment or relapse or progress after autologous hematopoietic stem cell transplantation, and the treatment history at least include
Treatment by CD20 monoclonal antibody (Rituximab) except for CD20 negative
a chemotherapy regimen containing anthracyclines
According to the preliminary evaluation, staging and response evaluation recommendations for Hodgkin and non Hodgkin's lymphoma (2014 Edition), at least one measurable lesion was found in the screening period
Life expectancy 12 weeks
Baseline Eastern Cooperative Oncology Group (ECOG) score is 0 or 1
Adequate organ function
Renal function defined as:A serum creatinine of 1.5 x ULN or Estimated Glomerular Filtration Rate (eGFR) 60 mL/min/1.73 m^2
Liver function defined as:Alanine Aminotransferase (ALT) 5 x ULNBilirubin 2.0 mg/dl with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is 3.0 x ULN and direct bilirubin 1.5 x ULN
Must have a minimum level of pulmonary reserve defined as Grade 1 dyspnea and pulse oxygenation > 91% on room air
Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) 50%, confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)
No blood transfusion within 1 week before signing the informed consent, sufficient bone marrow reserve is available, which is defined as
Absolute neutrophil count (ANC) > 1000/l
Absolute lymphocyte count (ALC) 500/l
Platelets 50000/l
Hemoglobin > 8.0 g/dl, for patients with bone marrow invasion, hemoglobin > 6.0 g/dl can be considered into the group
Must have an apheresis product of non-mobilized cells accepted for manufacturing
If the patient uses the following drugs, the following conditions should be met
glucocorticoids: The treatment dose of glucocorticoids must be stopped 72 hours before BZ019 infusion. However, glucocorticoids of physiological alternative dose are allowed: prednisone or its equivalent 15 mg / day
Immunosuppression: Any immunosuppressive medication must be stopped 4 weeks prior to enrollment
Antiproliferative therapies other than lymphodepleting chemotherapy within two weeks of infusion
Antibody use including anti-CD20 therapy within 4 weeks prior to infusion or 5 half-lives of the respected antibody, whichever is longer
CNS disease prophylaxis must be stopped > 1 week prior to BZ019 infusion (e.g. intrathecal methotrexate)
Women of child-bearing age and all male subjects must agree to use effective contraceptive methods until BZ019 are no longer present in the body (detected by PCR)

Exclusion Criteria

Patients who have previously received any anti-CD45, anti-CD19 or anti-CD3 therapy
Patients who have previously received any adoptive T cell therapy or gene therapy products, including CAR-T therapy
Active Central Nervous System (CNS) involvement by malignancy or secondary CNS involvement
History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or self-immune disease with CNS involvement
Prior allogeneic HSCT
Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of infusion
Investigational medicinal product within the last 30 days prior to screening
Prior radiation therapy within 6 weeks of infusion
Patients with positive hepatitis B (HBsAg and / or HBcAb positive, except for those with positive surface antibody alone) or hepatitis C serological markers
HIV positive or Treponema pallidum positive patients
Patients with uncontrollable active or life-threatening bacterial, viral or fungal infection (e.g. blood culture positive 72 hours before infusion)
Patients with unstable angina and / or myocardial infarction within 6 months before screening, or patients with serious or uncontrollable other diseases (such as unstable or uncompensated respiratory, heart, liver or kidney diseases) during screening
Previous or concurrent malignancy with the following exceptions
Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study
A primary malignancy which has been completely resected and in complete remission for 5 years
Pregnant or nursing (lactating) women
Patients with uncontrolled arrhythmia
Patients on oral anticoagulation therapy within 1 week prior to BZ019 infusion
Patients with active neurological auto immune or inflammatory disorders(e.g. Guillain Barre Syndrome, Amyptrophic Lateral Sclerosis)
Other protocol-related inclusion/exclusion may apply
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.